Table 3.
2014 Outcome | 2013 Frailty Category |
Crude 2014 Incidence per 1,000 beneficiaries |
Model 1* | Model 2* | Model 3* |
---|---|---|---|---|---|
OR (95%CI) | AOR (95%CI) | AOR (95%CI) | |||
Death | |||||
Non-Frail/Prefrail | 45 | 1.00 (REF) | 1.00 (REF) | 1.00 (REF) | |
Mildly Frail | 124 | 2.97 (2.78, 3.17) | 2.47 (2.31, 2.64) | 1.74 (1.62, 1.88) | |
Moderately Frail | 276 | 8.02 (7.39, 8.70) | 6.06 (5.56, 6.59) | 2.38 (2.13, 2.66) | |
Severely Frail | 412 | 14.70 (11.06, 19.54) | 11.94 (8.89, 16.05) | 2.74 (1.98, 3.78) | |
Hospitalization | |||||
Non-Frail/Prefrail | 181 | 1.00 | 1.00 | 1.00 | |
Mildly Frail | 324 | 2.17 (2.09, 2.25) | 2.05 (1.97, 2.13) | 1.69 (1.62, 1.77) | |
Moderately Frail | 450 | 3.71 (3.49, 3.94) | 3.37 (3.17, 3.59) | 2.03 (1.88, 2.20) | |
Severely Frail | 574 | 6.09 (4.60, 8.05) | 5.58 (4.21, 7.38) | 2.34 (1.74, 3.14) | |
Emergency Department Visit | |||||
Non-Frail/Prefrail | 337 | 1.00 | 1.00 | 1.00 | |
Mildly Frail | 523 | 2.16 (2.09, 2.24) | 2.02 (1.95, 2.09) | 1.78 (1.71, 1.84) | |
Moderately Frail | 638 | 3.47 (3.27, 3.69) | 3.09 (2.91, 3.29) | 2.26 (2.09, 2.44) | |
Severely Frail | 750 | 5.90 (4.29, 8.11) | 5.25 (3.82, 7.23) | 2.97 (2.14, 4.13) | |
Injury † | |||||
Non-Frail/Prefrail | 94 | 1.00 | 1.00 | 1.00 | |
Mildly Frail | 163 | 1.87 (1.77, 1.97) | 1.68 (1.59, 1.77) | 1.62 (1.53, 1.72) | |
Moderately Frail | 221 | 2.72 (2.50, 2.96) | 2.25 (2.06, 2.46) | 2.09 (1.87, 2.33) | |
Severely Frail | 173 | 2.00 (1.29, 3.12) | 1.64 (1.05, 2.56) | 1.43 (0.90, 2.26) | |
Model 1: Unadjusted
Model 2: Adjusted for sex, age category, race, and residence
Model 3: Adjusted for sex, age category, race, residence, PD status, neurologist care, nursing facility residence, deep brain stimulation, Combined Comorbidity Score, and mean daily levodopa equivalent dosage
P-value for linear trend for all analyses was <0.0001
Out of subset sample restricted to individuals with any PD claim in 2014 (n=55,568)